Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Dec;72(6):1329-33; discussion 1333-4.
doi: 10.1016/j.urology.2008.06.062. Epub 2008 Oct 1.

Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer

Andreas Blana  1 , Sebastian Rogenhofer, Roman Ganzer, Jens-Claudio Lunz, Martin Schostak, Wolf F Wieland, Bernhard Walter
Affiliations

Eight years' experience with high-intensity focused ultrasonography for treatment of localized prostate cancer

Andreas Blana et al. Urology. 2008 Dec.

Abstract

Objectives: To report on the long-term results of high-intensity focused ultrasonography (HIFU) in the treatment of localized prostate cancer.

Methods: Patients with clinical Stage T1-T2N0M0, biopsy-proven, localized prostate cancer, with a serum prostate-specific antigen (PSA) level of <or=20 ng/mL, Gleason score of <or=7, and with no previous curative prostate cancer treatment, were included. All patients underwent HIFU using the Ablatherm device and were required to have a minimal follow-up of 3 years after the last HIFU session to be included in this analysis. Follow-up included PSA measurement and biopsy performed 3-6 months after treatment and in conjunction with an increasing PSA level. Biochemical failure was defined according to the Phoenix definition (PSA nadir + 2 ng/mL). In determining the disease-free survival rate, treatment was considered to have failed if any of the following occurred: biochemical failure, positive biopsy findings, or the initiation of salvage treatment.

Results: The study included 163 patients. Within the 4.8 +/- 1.2 years of follow-up, no patient died of prostate cancer. Of the 163 patients, 86.4% achieved a PSA nadir of <1 ng/mL and 92.7% had negative post-treatment biopsy findings. The actuarial biochemical survival rate at 5 years was 75%. The actuarial disease-free survival rate at 5 years was 66%, with salvage treatment initiated for 12% of the patients. On multivariate analysis, the pretreatment PSA level was the only statistically significant predictive factor of recurrence (P = .005).

Conclusions: The results after long-term follow-up have indicated that HIFU is an efficient and safe treatment for patients with localized prostate cancer.

PubMed Disclaimer